ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE HUNTER HALL GLOBAL VALUE LIMITED PRELIMINARY RESULTS TO 30 JUNE 2009
Following comments on Sirtex from the above report
"Australian liver cancer treatment company Sirtex rose 12% over the year to June 2009, delivering outstanding 2009 full year financial results. Product revenue rose 72% to exceed $65.6m with Europe and the U.S sales growing 117% and 28%, respectively. Operational cash flow rose to $20m, up 426% on the previous corresponding period, while net profit before tax increased a staggering 640%. With a strong balance sheet, nil borrowings and steady cash flow, we believe Sirtex has excellent momentum."
